It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC.
- Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? (0:11)
- What has the CheckMate 040 Cohort 5 study taught us about the clinical impact of nivolumab in these patients? (1:04)
- What did we learn from this meeting about the efficacy and safety of hepatic arterial infusion chemotherapy in combination with sintilimab? (2:32)
- Which of the advances in immune checkpoint inhibitors do you consider to be particularly promising? (4:03)
Disclosures: Dr Bruno Sangro has received consultancy and/ or speaker fees from Adaptimmune, AstraZeneca, Bayer, BMS, Boston Scientific, BTG, Eli Lilly, Ipsen, Roche, Sirtex and Terumo; and research grants (to Institution) from BMS and Sirtex.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Cancer
Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Ahmed Kaseb, ESMO 2019 – Nivolumab plus ipilimumab in HCC
We joined Ahmed Kaseb (M.D. Anderson Cancer Center) at ESMO 2019 to discuss recent findings from the randomised, open-label, perioperative phase 2 study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma (NCT03222076). Questions 1. What are the major unmet needs in the treatment of resectable hepatocellular carcinoma (HCC)? (00:02) 2. […]
Viktor Grünwald- ECCO 2017
Combination therapy with lenvatinib and everolimus in metastatic renal cell carcinoma – why did this combination succeed where others failed? Katrina Mountfort, Touch Medical Media, Reading, UK, Metastatic renal cell carcinoma (mRCC) is associated with a poor prognosis, with a 5-year survival rate of only 8%.1 Within the last 10 years, a number of potent […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!